TAF Monotherapy Versus ETV Combined With TAF on the Efficacy and Prognosis of Immunotherapy for Hepatitis B-Related Hepatocellular Carcinoma

NCT07253220 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Hepatitis B
Hepatocellular Carcinoma (HCC)

Interventions

DRUG: The arm will receive combination therapy (entecavir 0.5 mg once daily plus TAF 25 mg once daily); after HBV DNA becomes undetectable, the combination group will switch to TAF monotherapy.
DRUG: TAF monotherapy

Sponsor

Sun Yat-sen University